

PAXMAN publishes newsletter on the company's expansion in Africa and Asia, and three poster presentations at ESMO in Barcelona

Today, PAXMAN publishes the September 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.

This issue highlights PAXMAN's upcoming launch in South Africa, where the company recently achieved market approval, and CEO Richard Paxman comments on the recently signed distribution agreement in Pakistan.

The newsletter also includes articles on the continued positive development in Oceania, the ongoing development of a prototype machine to prevent CIPN (nerve damage in hands and feet) together with National University Hospital, Singapore and three upcoming poster presentations at the ESMO conference in Barcelona on clinical studies where scalp cooling from PAXMAN was used.

Also, be sure to read PAXMAN's interim report for the second quarter of 2019, which is now available in [Swedish](#) and [English](#).

To read the newsletter, and subscribe to receive upcoming issues, follow this link:

<http://bit.ly/paxsep19en>

PAXMAN's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on PAXMAN's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[PAXMAN publishes newsletter on the company's expansion in Africa and Asia, and three poster presentations at ESMO in Barcelona](#)